The priority review user fee required by this subsection shall be due upon the submission of a human
drug application under section 505 (b)(1) or section 351 (a) of the Public Health Service Act for which the priority review voucher is used.
The sponsor of a material threat medical countermeasure
application that receives a priority review voucher
under this
section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human
drug for which an
application under section 505 (b)(1) or
section 351 (a) of the Public Health Service Act will be submitted after the date of the approval of the material threat medical countermeasure
application.